Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Gains from Sales and Divestitures (2018 - 2023)

Historic Gains from Sales and Divestitures for Dianthus Therapeutics (DNTH) over the last 3 years, with Q4 2023 value amounting to $6495.0.

  • Dianthus Therapeutics' Gains from Sales and Divestitures fell 9151.41% to $6495.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $6495.0, marking a year-over-year decrease of 9151.41%. This contributed to the annual value of $6495.0 for FY2023, which is 9151.41% down from last year.
  • Per Dianthus Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $6495.0 for Q4 2023, which was down 9151.41% from $6495.0 recorded in Q3 2023.
  • Dianthus Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $76539.0 during Q4 2022, with a 5-year trough of $6495.0 in Q3 2023.